Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB0025 vs tislelizumab in nonsquamous NSCLC
NCT07383116Phase 3Not yet recruiting
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Start
- Jan 2026
- Primary completion
- Apr 2028
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of sotiburafusp alfa in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd.. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
sotiburafusp alfa
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT07383116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07383116.